Analyzing non-coding RNA in patients with acute ischemic stroke undergoing endovascular treatment
Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)
This study is trying to see if certain types of RNA in patients with acute ischemic stroke can help predict how well they will do after receiving endovascular treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Nanjing First Hospital, Nanjing Medical University Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT04230785 on ClinicalTrials.gov |
What this trial studies
This study investigates the expression patterns of circular RNA (circRNA), long non-coding RNA (lncRNA), and micro-RNA (miRNA) in patients with acute ischemic stroke who are treated with endovascular therapy. Using next-generation sequencing, the study aims to identify potential biomarkers and regulators that could indicate the progression and prognosis of the condition. Additionally, it will evaluate the impact of endovascular treatment on immune responses in these patients. The findings may lead to the development of predictive models for patient outcomes based on the identified non-coding RNAs.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have confirmed acute ischemic stroke and are within 24 hours of symptom onset, eligible for endovascular therapy.
Not a fit: Patients with a history of hemorrhagic infarction, chronic kidney or liver diseases, or active malignant diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new biomarkers for assessing the prognosis of acute ischemic stroke and improve treatment strategies.
How similar studies have performed: While the role of non-coding RNAs in stroke is an emerging field, similar studies have shown promise in identifying biomarkers for various conditions, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 years or older * Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan * Within 24 hours of symptom onset and treat with endovascular therapy * Good performance status * Signed an approved informed consents Exclusion Criteria: * a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases
Where this trial is running
Nanjing, Jiangsu
- Nanjing First Hospital, Nanjing Medical University — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Junshan Zhou, M.D
- Email: zhjsh333@126.com
- Phone: +8602587726218
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.